
### [NCIT:C5029](http://purl.obolibrary.org/obo/NCIT_C5029)
**Label:** Extrahepatic Bile Duct Sarcoma

**Subclasses:** [NCIT:C5847](http://purl.obolibrary.org/obo/NCIT_C5847) (Extrahepatic Bile Duct Embryonal Rhabdomyosarcoma), [NCIT:C96951](http://purl.obolibrary.org/obo/NCIT_C96951) (Extrahepatic Bile Duct Kaposi Sarcoma), [NCIT:C5860](http://purl.obolibrary.org/obo/NCIT_C5860) (Extrahepatic Bile Duct Rhabdomyosarcoma), [NCIT:C5848](http://purl.obolibrary.org/obo/NCIT_C5848) (Extrahepatic Bile Duct Leiomyosarcoma), 

**Class expressions from DL-Learner:**

- [UBERON:0002423](http://purl.obolibrary.org/obo/UBERON_0002423) (hepatobiliary system) 53.57%
- Thing 53.00%
- [NCIT:C45714](http://purl.obolibrary.org/obo/NCIT_C45714) (Epithelial Tissue) 38.93%
- [NCIT:C45714](http://purl.obolibrary.org/obo/NCIT_C45714) (Epithelial Tissue) and (not ([NCIT:C39066](http://purl.obolibrary.org/obo/NCIT_C39066) (Erythropoietin Neuroprotection Pathway))) 38.93%
- [NCIT:C45714](http://purl.obolibrary.org/obo/NCIT_C45714) (Epithelial Tissue) and (not ([NCIT:C39059](http://purl.obolibrary.org/obo/NCIT_C39059) (Map Kinase Inactivation of SMRT Corepressor Pathway))) 38.93%
- [NCIT:C45714](http://purl.obolibrary.org/obo/NCIT_C45714) (Epithelial Tissue) and (not ([NCIT:C39058](http://purl.obolibrary.org/obo/NCIT_C39058) (EGF Signaling Pathway))) 38.93%
- [NCIT:C45714](http://purl.obolibrary.org/obo/NCIT_C45714) (Epithelial Tissue) and (not ([NCIT:C39056](http://purl.obolibrary.org/obo/NCIT_C39056) (Vesicle Transport Pathway))) 38.93%
- [NCIT:C45714](http://purl.obolibrary.org/obo/NCIT_C45714) (Epithelial Tissue) and (not ([NCIT:C39055](http://purl.obolibrary.org/obo/NCIT_C39055) (Phospholipid Signaling Pathway))) 38.93%
- [NCIT:C45714](http://purl.obolibrary.org/obo/NCIT_C45714) (Epithelial Tissue) and (not ([NCIT:C39054](http://purl.obolibrary.org/obo/NCIT_C39054) (Extracellular Matrix Binding Pathway))) 38.93%
- [NCIT:C45714](http://purl.obolibrary.org/obo/NCIT_C45714) (Epithelial Tissue) and (not ([NCIT:C39040](http://purl.obolibrary.org/obo/NCIT_C39040) (CTCF Pathway))) 38.93%
- [NCIT:C45714](http://purl.obolibrary.org/obo/NCIT_C45714) (Epithelial Tissue) and (not ([NCIT:C39021](http://purl.obolibrary.org/obo/NCIT_C39021) (Cell Migration Pathway))) 38.93%
- [NCIT:C45714](http://purl.obolibrary.org/obo/NCIT_C45714) (Epithelial Tissue) and (not ([NCIT:C39016](http://purl.obolibrary.org/obo/NCIT_C39016) (EGF Receptor Downregulation by CBL Pathway))) 38.93%
- [NCIT:C45714](http://purl.obolibrary.org/obo/NCIT_C45714) (Epithelial Tissue) and (not ([NCIT:C39013](http://purl.obolibrary.org/obo/NCIT_C39013) (Estrogen Receptor Regulation by CARM1 Pathway))) 38.93%
- [NCIT:C45714](http://purl.obolibrary.org/obo/NCIT_C45714) (Epithelial Tissue) and (not ([NCIT:C39011](http://purl.obolibrary.org/obo/NCIT_C39011) (Cardiac Hypertrophy Pathway))) 38.93%
- [NCIT:C45714](http://purl.obolibrary.org/obo/NCIT_C45714) (Epithelial Tissue) and (not ([NCIT:C3901](http://purl.obolibrary.org/obo/NCIT_C3901) (Compound Nevus))) 38.93%


